{"doc_id": "33357606", "type of study": "Therapy", "title": "", "abstract": "Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.\nCovid-19 confers substantial risk for the >400,000 patients who receive methadone for the treatment of opioid use disorder (OUD) and methods for safely dispensing large quantities of methadone to patients are lacking.\nThis study evaluated the MedMinder \"Jon\", an electronic and cellular-enabled pillbox that provides real-time monitoring to remotely manage take-home doses of methadone using a 12-week, within-subject, Phase II (NCT03254043) trial.\nWe transitioned all participants from liquid to tablet methadone one week prior to randomization.\nParticipants completed both treatment-as-usual and electronic pillbox conditions before choosing a condition in a final \"choice phase\".\nWe assessed feasibility, satisfaction, and safety outcomes during the exit interview.\nOverall, we randomized 25 participants, 24 (96.0%) completed >1 study session, and 21 (84.0%) completed the exit interview.\nWe dispensed 167.92\u00a0g (1,974 doses) of methadone.\nParticipants would use the pillbox again (86.3%) and recommend it to others (95.4%).\nOverall, 52.4% selected the pillbox in the choice condition and those who did not cited issues related to study requirements.\nLess than 1% of pillbox alerts were for medication being consumed outside the dosing window and we observed no evidence of actual or attempted methadone diversion.\nWe were able to adequately manage patients who would not otherwise qualify for large quantities of take-home methadone when we dispensed methadone tablets via a secure pillbox.\nThe integration of a commercially available pillbox into routine clinic operations increases opportunity for dispensing medication.\nOur data support remote monitoring of methadone take-home doses and may inform clinic practices related to Covid-19.\nCopyright \u00a9 2020 Elsevier Inc. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "dispensing methadone", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 71}, {"term": "opioid use disorder", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 107}, {"term": "Covid-19 pandemic", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 136}, {"term": "large quantities of take-home methadone", "negation": "negated", "UMLS": {}, "start": 79, "end": 118}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 115}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic .", "Evidence Elements": {"Participant": [{"term": "dispensing methadone", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 71}, {"term": "opioid use disorder", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 107}, {"term": "Covid-19 pandemic", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 136}], "Intervention": [{"term": "Technology-assisted methadone take-home dosing", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 46, "has_chemical": [{"text": "methadone", "maps_to": "C0025605:methadone", "start": 20, "end": 29}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "Covid-19 confers substantial risk for the > 400,000 patients who receive methadone for the treatment of opioid use disorder ( OUD ) and methods for safely dispensing large quantities of methadone to patients are lacking .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This study evaluated the MedMinder \" Jon \" , an electronic and cellular-enabled pillbox that provides real-time monitoring to remotely manage take-home doses of methadone using a 12-week , within-subject , Phase II ( NCT03254043 ) trial .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "MedMinder \" Jon \"", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 42, "has_relation": "N/A"}], "Outcome": [{"term": "take-home doses of methadone", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 170}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We transitioned all participants from liquid to tablet methadone one week prior to randomization .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "liquid to tablet methadone", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 64, "has_chemical": [{"text": "methadone", "maps_to": "C0025605:methadone", "start": 17, "end": 26, "has_form": ["tablet", "liquid"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Participants completed both treatment-as-usual and electronic pillbox conditions before choosing a condition in a final \" choice phase \" .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "treatment-as-usual", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 46, "has_procedure": [{"text": "treatment", "maps_to": "C0087111:treatment", "start": 0, "end": 9}], "has_relation": "N/A"}, {"term": "electronic pillbox", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 69, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We assessed feasibility , satisfaction , and safety outcomes during the exit interview .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "feasibility", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 23}, {"term": "satisfaction", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 38}, {"term": "safety outcomes", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 60}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Overall , we randomized 25 participants , 24 ( 96.0 % ) completed > 1 study session , and 21 ( 84.0 % ) completed the exit interview .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "We dispensed 167.92 g ( 1,974 doses ) of methadone .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Participants would use the pillbox again ( 86.3 % ) and recommend it to others ( 95.4 % ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "pillbox", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 34, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Overall , 52.4 % selected the pillbox in the choice condition and those who did not cited issues related to study requirements .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "pillbox", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 37, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": [{"term": "52.4 %", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 16}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Less than 1 % of pillbox alerts were for medication being consumed outside the dosing window and we observed no evidence of actual or attempted methadone diversion .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "pillbox alerts", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 31, "has_chemical": [{"text": "pillbox alerts", "maps_to": "C0718338:alerts", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "actual or attempted methadone", "negation": "negated", "UMLS": {}, "start": 124, "end": 153}], "Observation": [], "Count": [{"term": "than 1 %", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 13}]}, "Evidence Propositions": []}, {"Section": "DISCUSSION", "Text": "We were able to adequately manage patients who would not otherwise qualify for large quantities of take-home methadone when we dispensed methadone tablets via a secure pillbox .", "Evidence Elements": {"Participant": [{"term": "large quantities of take-home methadone", "negation": "negated", "UMLS": {}, "start": 79, "end": 118}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DISCUSSION", "Text": "The integration of a commercially available pillbox into routine clinic operations increases opportunity for dispensing medication .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DISCUSSION", "Text": "Our data support remote monitoring of methadone take-home doses and may inform clinic practices related to Covid-19 .", "Evidence Elements": {"Participant": [{"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 115}], "Intervention": [{"term": "remote monitoring of methadone take-home doses", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 63, "has_chemical": [{"text": "methadone", "maps_to": "C0025605:methadone", "start": 21, "end": 30}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier Inc . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}